Keymed Biosciences announced that the first patient has been dosed in the Phase I trial of CM350. CM350 is a GPC3xCD3 bispecific antibody developed by the Company for the treatment of solid tumors. The phase I trial is being conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of CM350 in patients with solid tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 HKD | +3.86% | +17.48% | -28.82% |
Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
Mar. 27 | KeyMed Biosciences’ Attributable Loss Widens in 2023 | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.82% | 1.19B | |
-1.93% | 104B | |
+1.72% | 97.42B | |
+0.79% | 22.2B | |
-17.89% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.10% | 15.06B | |
+3.77% | 13.98B | |
+33.24% | 11.66B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350